UMN Lands Patent for Using Synthetic DNA to Target Heart Failure

The University of Minnesota has won a patent on a new method of treatment for coronary disease using recent advances in synthetic DNA to address an underlying cause of chronic heart failure. If successful the technology could become an early pioneer in the emerging field of translating advances in synthetic DNA into actual medical applications. Read more.

Share this post

Related News